Advance Paradigm Lescol and Pravachol switch programs help agents gain market share.
Executive Summary
ADVANCE PARADIGM LESCOL, PRAVACHOL SWITH PROGRAM has helped the two newer cholesterol-lowering agents gain market share at an IPA-model HMO, although Merck's Zocor continues to hold the number one position, according to a poster presentation at the Academy of Managed Care Pharmacy meeting in Orlando Nov. 1. Advance Paradigm began a test of the switch program in March at a 60,000 patient IPA-model HMO. The market share for Sandoz' Lescol (fluvastatin) increased from 19.5% to 24.9%, while Bristol-Myers Squibb's Pravachol (pravastatin) moved from a 17.9% share to 22.4%. Zocor (simvastatin) saw its market share drop from 40% to 34.6%, while Merck's Mevacor (lovastatin) fell from a 25.7% share to 18.1%.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: